Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prothena Corp Public (PRTA) Cash & Equivalents (2016 - 2025)

Prothena Corp Public (PRTA) has 14 years of Cash & Equivalents data on record, last reported at $307.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 34.77% year-over-year to $307.5 million; the TTM value through Dec 2025 reached $307.5 million, down 34.77%, while the annual FY2025 figure was $307.5 million, 34.77% down from the prior year.
  • Cash & Equivalents reached $307.5 million in Q4 2025 per PRTA's latest filing, down from $330.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $710.4 million in Q4 2022 and bottomed at $307.5 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $517.2 million, with a median of $531.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 96.05% in 2021, then tumbled 36.29% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $579.1 million in 2021, then increased by 22.68% to $710.4 million in 2022, then dropped by 12.89% to $618.8 million in 2023, then dropped by 23.83% to $471.4 million in 2024, then tumbled by 34.77% to $307.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $307.5 million in Q4 2025, $330.8 million in Q3 2025, and $371.4 million in Q2 2025.